Siemens Healthcare is teaming up with Mauna Kea Technologies, inventor of Cellvizio, to evaluate its benefits in interventional radiology procedures.
Cellvizio's needle-based optical biopsy technology will be used in combination with Siemens angiography and interventional x-ray and CT systems in two clinical studies taking place at the Hôpital Européen Georges Pompidou in Paris and the University Hospital in Strasbourg, France.
The trials will focus on procedures involving the lung, liver, and kidney. Patients will receive a full examination using a combination of Cellvizio and Siemens' imaging and guiding technologies.
Cellvizio is currently not approved for interventional radiology applications and is considered experimental in these protocols, the firms said.